SMARCB1 and epithelioid sarcoma: Given the regulatory approval of tazemetostat as a salvage therapy in patients with epithelioid sarcoma, close monitoring will also be required in patients with these INI1-deficient tumors to ensure that they are unable to undergo glial mimicry.